Ajanta Pharma launches dermatology products
Cardiology, ophthalmic and ENT products specialist Ajanta Pharma has launched new products in the Rs 1,300-crore dermatology segment in the country.
By PTI |
MUMBAI: Cardiology, ophthalmic and ENT products specialist Ajanta Pharma has launched new products in the Rs 1,300-crore dermatology segment in the country.
The products are Vaniza and Revanesse. While Vaniza is an anti-scar product, with the US Food and Drug Administration approval, Revanesse, made by Canadian company Prollenium Medical Technologies, has been launched to take on Botox, Ajanta Pharma Executive Director Yogesh M Agarwal told media.
A 15 gram pack of Vaniza costs Rs 450, while Revanesse is an injectable product, priced at Rs 11,000, he said.
Vaniza is for use on fresh wounds. Its manufacturing technology has been given to Orient Europharma of Taiwan, for Taiwan, Macau, Hong Kong, Singapore and Malaysian markets, while Ajanta Pharma would get royalty for seven years, he said.
Both Revanesse and Botox are biotech products that help replenish lost hyaluronic acid in the skin, leaving it well hydrated and supple.
The products are Vaniza and Revanesse. While Vaniza is an anti-scar product, with the US Food and Drug Administration approval, Revanesse, made by Canadian company Prollenium Medical Technologies, has been launched to take on Botox, Ajanta Pharma Executive Director Yogesh M Agarwal told media.
A 15 gram pack of Vaniza costs Rs 450, while Revanesse is an injectable product, priced at Rs 11,000, he said.
Vaniza is for use on fresh wounds. Its manufacturing technology has been given to Orient Europharma of Taiwan, for Taiwan, Macau, Hong Kong, Singapore and Malaysian markets, while Ajanta Pharma would get royalty for seven years, he said.
Both Revanesse and Botox are biotech products that help replenish lost hyaluronic acid in the skin, leaving it well hydrated and supple.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
